New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.
The optimal time to measure PSA response to treatment is 9 months for patients with mHSPC to gauge risk for disease progression. In real-world patients with metastatic, hormone-sensitive prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results